🔎 Trials Near Me

Utama › Leukemia Mieloid Akut › Ohio › Cincinnati

Kajian klinikal Leukemia Mieloid Akut di Cincinnati, OH

20 kajian untuk Leukemia Mieloid Akut sedang mencari peserta di lokasi dalam dan sekitar Cincinnati (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
  • Good Samaritan Hospital - Cincinnati, Cincinnati
  • Oncology Hematology Care Inc-Kenwood, Cincinnati
  • Bethesda North Hospital, Cincinnati
  • dan 3 lagi
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Mengambil pesertaKajian pemerhatian
  • Cincinnati Children's Hospital Medical Center, Cincinnati
Umur 0 hingga 38 · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06131801

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Mengambil pesertaFasa 3
  • Oncology Hematology Care, Cincinnati
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06852222

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Mengambil pesertaFasa 1
  • Cincinnati Children's Hospital Medical Center, Cincinnati
Sehingga umur 21 · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07012044

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Mengambil pesertaFasa 3
  • Cincinnati Children's Hospital Medical Center, Cincinnati
6 Months – 21 Years · Semua jantina · Dikemas kini 17 Sep 2026 · NCT04293562

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

Mengambil pesertaKajian pemerhatian
  • University of Cincinnati, Cincinnati
Umur 0 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT07154823

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Mengambil pesertaFasa 3
  • US-Cincinnati OH-CINCY, Cincinnati
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT06652438

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

Mengambil pesertaFasa 3
  • US-Cincinnati OH-CINCY, Cincinnati
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Sep 2026 · NCT07223814

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

Mengambil pesertaFasa 1
  • University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
  • University of Cincinnati Cancer Center-West Chester, West Chester · 15 mi jauh
Umur 18 hingga 75 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT05886049

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Mengambil pesertaFasa 1
  • Cincinnati Children's Hospital Medical Center, Cincinnati
Umur 1 hingga 30 · Semua jantina · Dikemas kini 3 Ogo 2026 · NCT06177067

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Mengambil pesertaFasa 3
  • University of Cincinnati Medical Center (University Hospital), Cincinnati
Umur 18 hingga 75 · Semua jantina · Dikemas kini 17 Jul 2026 · NCT05429632

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Mengambil pesertaKajian pemerhatian
  • Cincinnati Children's Hospital, Cincinnati
Semua umur · Semua jantina · Dikemas kini 6 Jul 2026 · NCT01351545

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Mengambil pesertaFasa 1
  • Cincinnati Children's Hospital Medical Center, Cincinnati
  • University of Cincinnati, Cincinnati
Umur 13 ke atas · Semua jantina · Dikemas kini 5 Mei 2026 · NCT04771572

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

Mengambil pesertaFasa 1
  • Cincinnati Children's Hospital, Cincinnati
Sehingga umur 21 · Semua jantina · Dikemas kini 22 Apr 2026 · NCT05101551

Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)

Mengambil pesertaFasa 1/2
  • Cincinnati Children's Hospital Medical Center, Cincinnati
Umur 2 ke atas · Semua jantina · Dikemas kini 25 Feb 2026 · NCT05580601

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

Mengambil pesertaFasa 1
  • Cincinnati Children's Hospital Medical Center, Cincinnati
Umur 1 hingga 39 · Semua jantina · Dikemas kini 18 Feb 2026 · NCT03826992

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Mengambil pesertaFasa 2
  • Cincinnati Children's Hospital Medical Center, Cincinnati
3 Months · Semua jantina · Dikemas kini 12 Nov 2025 · NCT02143830

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

Mengambil pesertaFasa 1
  • Oncology Hematology Care, Cincinnati
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Mei 2025 · NCT06634394

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Mengambil pesertaFasa 1
  • University of Cincinnati, Cincinnati
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Nov 2024 · NCT06034275

Kajian Leukemia Mieloid Akut di bandar lain

Kajian lain di Cincinnati

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.